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Introduction
About 90% of patients with clinical presentation of acute
myocardial infarction (AMI) undergoing coronary angiog-
raphy have obstructive coronary artery disease (CAD)
(i.e. 50% stenosis). These patients have well-
established therapeutic management.1,2 However, 10% of
patients with AMI have no-significant epicardial CAD on
coronary angiography, that includes both patients with
normal coronary arteries and patients with mild coronary
atheromatosis (stenosis < 50%). The aetiology of the
myocardial necrosis is not immediately apparent, and
there are few data about therapeutic strategies.3,4
Importantly, identifying the pathophysiological mecha-
nism of myocardial infarction with no obstructive coro-
nary arteries (MINOCA) is key for prognostic assessment
and therapeutic approach.5–7
Case presentation
A 65-year-old Caucasian man, with history of hypertension
and type II diabetes mellitus, presented to our emergency
department with stuttering chest pain of 6 h duration, radi-
ating to the left arm and relieved by sublingual administra-
tion of short-acting nitrates.
The presenting electrocardiogram (ECG) showed an
atrial fibrillation with normal ventricular response and
negative-ischaemic Twaves in leads V1–V4. On admission,
the Hs-troponin I concentration was 0.149ng/mL, peaking
at 0.521ng/mL on the first day then down trending. D-
Dimer and C-reactive protein were normal. The echocar-
diogram showed preserved ejection fraction  55% with
normal regional motion, normal right sections, and trivial
mitral regurgitation.
The patient’s medical history included chronic kidney
disease (Stage III) and previous liver transplantation (HCV
related), whereby he was receiving immunosuppressive
therapy (everolimus). Ten years before the patient had un-
dergone mitral valvuloplasty for severe mitral regurgita-
tion. Furthermore, he was symptomatic for several
episodes of paroxysmal atrial fibrillationwith rapid ventric-
ular rate and a bicameral pacemaker has been implanted
because of sick sinus syndrome. On admission, the therapy
included Metoprolol 50mg/b.i.d. and oral anticoagulant.
Upon these data, differential diagnoses of chest pain were
considered including type 1 AMI, myocardial injury due to
tachyarrhythmias, myocarditis in immunodeficiency
patients, takotsubo syndrome, or non-cardiac chest pain.
As type 1 AMI was the most probable medical therapy for
non-ST-segment elevation acute coronary syndrome (ACS)
was initiated. The GRACE 2.0 and CRUSADE risk scores were
124 points (intermediate-risk) and 46 points (high-risk),
respectively.
Coronary angiography was performed 24h after admis-
sion, and an intermediate stenosis of the proximal tract of
left anterior descending (LAD) artery was observed. The op-
tical frequency-domain imaging (St. Jude Medical) was used
to further evaluate the underlying mechanism of the ACS.
This high-resolution intracoronary imaging showed, in the
proximal tract of the LAD, a smooth, mainly fibrotic coro-
nary plaque, without signs of rupture and/or erosion, and a
diffuse intimal thickening of the entire LAD. Calculated
minimal lumen area was 3.1 mm2, whereas area stenosis
was 57%, indicating a non-significant stenosis (Figure 1).8
The first clinical decision was to optimize anti-anginal
drug therapy by doubling the dose of Metoprolol (100mg/
b.i.d.). However, few days later new angina attacks oc-
curred, caused by slight efforts. Therefore, coronary angi-
ography was repeated and fractional flow reserve (FFR)
was performed to better characterize LAD stenosis. The in-
vasive FFR measurement, after intracoronary injection of
adenosine, was 0.90, confirming a non-significant stenosis
(Figure 2).
According to our systematic algorithm of investigation of
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atherosclerosis (MINOCA),9 we administered intracoronary
acetylcholine at increasing dosages. Low dose (50mg in
10ml of saline) elicited occlusive diffuse spasm, which in-
volved the medium and distal tracts of the LAD. The pa-
tient had chest pain, described as identical to that
occurring during spontaneous event. ECG was not informa-
tive because of pacemaker rhythm. Intracoronary nitrates
were rapidly administered resulting in the relief of both
coronary spasm and chest pain (Figure 3A, B). Beta-block-
ers were suspended and diltiazem was added to the
patient’s drug regimen and titrated up to 360mg/daily,
with no symptoms recurrence or hospital admission up to
12months later.
Discussion
A sizeable proportion of patients presenting with ACS are
found to have absent or only angiographically mild coro-
nary lesions. Dynamic changes in epicardial coronary artery
tone, alone or in combination with abnormalities of coro-
nary microcirculation, are an important cause of
MINOCA.3,5,6 It is worth noting that spasm can also occur at
the site of atherosclerotic plaques and in concomitance
with coronary stenoses at other sites. The susceptibility to
spasm can be unmasked by selective intracoronary admin-
istration of ergonovine or acetylcholine; the latter is an
endothelium-dependent vasodilator and a direct constric-
tor of vascular smooth muscle cells,10 because its dual ac-
tion on muscarinic receptors. Therefore, the impaired
vasodilatory response to intra-arterial administration of
acetylcholine results from several coexisting abnormalities
in endothelial function. Indeed, in arteries lacking endo-
thelium, or where endothelium is dysfunctional, the pre-
vailing effect is vasoconstriction.11
Intriguingly, in our patient, administration of low-dose
acetylcholine triggered focal coronary spasm not at the
level of the proximal atherosclerotic plaque, but rather
downstream. This suggests that endothelial dysfunction is
not responsible per se for coronary spasm, as its anatomical
hallmark (diffuse intimal thickening) was present along the
entire course of the LAD and was probably even more se-
vere at the site of the proximal atherosclerotic plaque.11–13
Our case suggests that a careful elucidation of the spe-
cific pathophysiological mechanism operating in each
Figure 1 Optical coherence tomography imaging of the left anterior descending artery showing a stenosis with a non-critical minimal luminal area of
3.1 mm2.
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individual patient presenting with ACS, is crucial for risk
stratification and optimization of pharmacological therapy.
Coronary epicardial or microvascular vasoconstriction/
spasm is a plausible mechanism of the syndrome in a subset
of these patients3,5,6 and should be systematically investi-
gated in MINOCA patients.14
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